MEDISEARCHER NEWS
United States · Rare diseases · FDA drug approval · 19 November 2026
In brief
- The US Food and Drug Administration (FDA) approved Infilbray (venglustat) on 18 November 2026, the first medicine specifically authorised to treat neurological symptoms of Gaucher disease type 3.
- The approval covers adults and children weighing at least 15 kilograms (approximately 33 pounds).
- Infilbray is a once-daily oral treatment designed to reduce the accumulation of certain fatty substances and can cross the blood-brain barrier.
- A 52-week Phase 3 trial involving 43 patients demonstrated statistically significant improvement across combined neurological measures compared with enzyme replacement therapy.
- Important safety concerns include depression, suicidal thoughts or behaviour, potential eye complications in younger patients and risks during pregnancy.
- Infilbray is not a cure for Gaucher disease. It is under regulatory review in the European Union and Japan but has not yet received approval in those markets.
The US Food and Drug Administration (FDA) has approved Infilbray (venglustat), the first medicine specifically authorised to treat neurological symptoms of Gaucher disease type 3. The decision, announced on 18 November 2026, introduces a treatment option for a rare inherited disorder that can progressively affect movement, coordination and cognitive function.
The approval covers adults and children weighing at least 15 kilograms (approximately 33 pounds). It is based on a Phase 3 clinical trial involving 43 patients, in which Infilbray demonstrated improvements in combined neurological assessments compared with enzyme replacement therapy.
What is Gaucher disease type 3?
Gaucher disease is a rare inherited lysosomal storage disorder caused by insufficient activity of an enzyme needed to break down certain fatty substances. As these substances accumulate in the body, they can damage organs and tissues.
Gaucher disease type 3, sometimes called chronic neuronopathic Gaucher disease, also affects the central nervous system.
Patients may experience neurological symptoms including:
- Problems with balance and coordination
- Abnormal eye movements
- Difficulty speaking or controlling movement
- Memory and cognitive difficulties
- Progressive neurological impairment
Existing enzyme replacement therapies can help manage systemic manifestations of Gaucher disease, including complications affecting the liver, spleen and blood. However, these treatments have limited ability to address neurological symptoms because they do not adequately cross the blood-brain barrier.
How does Infilbray work?
Infilbray contains venglustat, a glucosylceramide synthase inhibitor. Rather than replacing the deficient enzyme, it reduces production of certain fatty substances that accumulate in Gaucher disease.
Importantly, venglustat can cross the blood-brain barrier, allowing it to act within the central nervous system.
This distinguishes Infilbray from established enzyme replacement therapies, which primarily address manifestations of the disease outside the brain.
Infilbray is taken orally once daily, whereas enzyme replacement therapies are generally administered by intravenous infusion.
However, Infilbray is not a cure for Gaucher disease. Its approval represents a new treatment approach for neurological manifestations, rather than a reversal of the underlying inherited disorder.
What did the clinical trial show?
The FDA’s decision was supported by the LEAP2MONO Phase 3 study (NCT05222906), a randomised, double-blind trial involving 43 patients aged 12 years and older with Gaucher disease type 3.
Participants had previously received enzyme replacement therapy and achieved stabilisation of their systemic disease manifestations.
Over 52 weeks, patients received either once-daily oral venglustat or intravenous imiglucerase, an established enzyme replacement treatment administered every two weeks.
Researchers assessed neurological outcomes using measures of motor coordination and cognitive performance, including a modified Scale for the Assessment and Rating of Ataxia and the Repeatable Battery for the Assessment of Neuropsychological Status.
According to Sanofi, the trial met its primary endpoint, demonstrating statistically significant superiority for Infilbray across the combined neurological assessments (p=0.0137).
The FDA confirmed improvement on the combined neurological measure compared with enzyme replacement therapy.
These findings support the medicine’s effectiveness for its approved indication. However, the trial was relatively small, reflecting the rarity of the condition, and the longer-term durability of neurological benefits remains under investigation.
The study’s open-label follow-up phase is ongoing.
What are the side effects and safety warnings?
Infilbray has important safety considerations that patients and healthcare professionals must assess before treatment.
Adverse reactions reported during the clinical study included gastrointestinal symptoms and changes in mood.
According to Sanofi, among patients receiving Infilbray, reported adverse reactions included:
- Diarrhoea: 14%
- Nausea: 14%
- Depression: 10%
- Gastroenteritis: 10%
- Vomiting: 10%
The FDA also highlighted serious psychiatric risks, including suicidal thoughts and behaviour.
Additional warnings concern potential lens opacification in paediatric patients and embryofoetal toxicity. Some of these concerns arise from animal studies and should not be interpreted as confirmed rates of harm in humans.
Patients and caregivers should discuss the full prescribing information, monitoring requirements and potential risks with their specialist. Any new or worsening mood symptoms should be reported promptly.
Is Infilbray available in Europe, the UK or Australia?
As of 19 November 2026, Infilbray has received FDA approval in the United States.
Sanofi has confirmed that the medicine is undergoing regulatory review in the European Union and Japan. An EU orphan designation does not itself constitute marketing authorisation.
Approval in the United States does not automatically make a medicine available through healthcare systems in other countries.
For European patients, further steps may include:
- Completion of the European Medicines Agency’s regulatory assessment
- A European Commission marketing authorisation decision, if recommended
- National pricing and reimbursement assessments
- Country-specific launch and distribution arrangements
Separate regulatory and access decisions would also be required in markets such as the UK and Australia. No approval or reimbursement status in those countries is established by the US announcement.
Even within the United States, regulatory approval does not necessarily mean immediate availability at every treatment centre or guaranteed insurance coverage.
Why this approval matters for rare-disease treatment
For many patients with Gaucher disease type 3, managing neurological complications has remained a major unmet medical need.
Enzyme replacement therapy has transformed treatment of systemic disease manifestations, but neurological complications have remained difficult to address.
Infilbray introduces an FDA-approved approach designed to reduce disease-related substance accumulation within the brain itself.
Its approval is therefore an important milestone in rare-disease medicine and illustrates how therapies capable of reaching the central nervous system may address symptoms that existing treatments cannot adequately control.
Nevertheless, the results should be interpreted in the context of a small clinical trial, and continued follow-up will be important to establish longer-term outcomes and safety.
What happens next?
Attention will now turn to the commercial introduction of Infilbray in the United States, ongoing clinical follow-up and regulatory decisions in other markets.
For European patients, the most important next milestone is the outcome of the EU regulatory review, followed by national decisions affecting pricing, reimbursement and access.
MediSearcher will continue monitoring regulatory developments and patient access to Infilbray in the United States and Europe.
Frequently asked questions
What is Infilbray used for?
Infilbray (venglustat) is FDA-approved to treat neurological symptoms of Gaucher disease type 3 in adults and children weighing at least 15 kilograms. It targets the production of certain fatty substances that accumulate in the disease.
Is Infilbray a cure for Gaucher disease?
No. Infilbray is a treatment for neurological manifestations of Gaucher disease type 3. It does not correct the underlying inherited genetic disorder, and longer-term outcomes remain under investigation.
How is Infilbray different from enzyme replacement therapy?
Enzyme replacement therapies help manage systemic manifestations of Gaucher disease but do not adequately cross the blood-brain barrier. Infilbray reduces production of certain fatty substances and can act within the central nervous system.
What did the Infilbray clinical trial find?
The 52-week LEAP2MONO Phase 3 trial involving 43 patients demonstrated statistically significant improvement on combined neurological assessments compared with enzyme replacement therapy. The trial’s small size and ongoing follow-up remain important considerations.
What are the main safety concerns?
Reported adverse reactions included gastrointestinal symptoms and depression. Important warnings also include suicidal thoughts or behaviour, potential eye complications in younger patients and risks during pregnancy. Patients should review the full prescribing information with their specialist.
Is Infilbray approved in Europe?
As of 19 November 2026, Infilbray is approved in the United States and remains under regulatory review in the European Union. EU review does not mean the medicine is already authorised, reimbursed or available to patients in individual European countries.
Will insurance cover Infilbray in the United States?
FDA approval does not guarantee insurance coverage. Actual access will depend on commercial availability, individual insurance arrangements and any applicable coverage requirements.
The bottom line
The FDA’s approval of Infilbray represents an important advance for people living with Gaucher disease type 3, particularly because neurological complications have historically been difficult to address with existing enzyme replacement treatments.
The LEAP2MONO trial provides evidence of improvement across combined neurological measures, although the relatively small patient population and limited duration of controlled follow-up mean important questions remain about long-term outcomes.
Infilbray is a new FDA-approved treatment option, not a cure. Patients outside the United States must await separate regulatory and access decisions before its availability can be established.
Reviewed by: Dr Mattias Hagman, PhD
Editorial review: MediSearcher reviewed the FDA’s 18 November 2026 approval announcement, supporting clinical trial information and manufacturer disclosures concerning Infilbray (venglustat). The review distinguishes confirmed regulatory approval and clinical findings from longer-term treatment uncertainties, potential safety risks and pending regulatory decisions outside the United States.
Last reviewed: 19 November 2026
Sources and verification
- US Food and Drug Administration: FDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher Disease, 18 November 2026 — primary regulatory announcement, approved indication, supporting clinical evidence and safety considerations.
- Sanofi: Infilbray approval announcement, 18 November 2026 — manufacturer information on the LEAP2MONO trial, neurological outcomes, reported adverse reactions and international regulatory review.
- ClinicalTrials.gov: LEAP2MONO Phase 3 study (NCT05222906) — clinical trial registration, study design, eligibility criteria and follow-up information.
This article provides general health and regulatory information and does not replace individual medical advice. Treatment decisions for Gaucher disease require specialist assessment of clinical circumstances, potential benefits, safety risks and available alternatives. Patients should not start, stop or change prescribed treatments without advice from an appropriate healthcare professional. Regulatory guidance and access arrangements may change after publication.